Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US29479A1088
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MTSR883
ERAS
Erasca Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Erasca Inc
ISIN
US29479A1088
TICKER
ERAS
MIC
XNAS
REUTERS
ERAS.OQ
BLOOMBERG
ERAS US
Fr., 12.06.2026       Erasca
US29479A1088

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. (“Erasca” or “the Company”) (NASDAQ: ERAS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       Erasca
US29479A1088

NEW YORK, June 11, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"). A class...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       Erasca
US29479A1088

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) securities during the period of January 14, 2025 through April 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Erasca investments, you have un...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 12.06.2026       Erasca
US29479A1088

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Erasca, Inc. (NASDAQ: ERAS) between January 14, 2025 and April 26, 2026, inclusive (the “Class Period”). Erasca develops oncology therapies. For more information, submit a form, email attorney Phillip Kim, or give us a c...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Erasca
US29479A1088

SAN DIEGO, June 11, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, inclusive (the "Class Period"), have until August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit. Captioned...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Erasca
US29479A1088

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc (“Erasca” or the “Company”) (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. This press release...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Erasca
US29479A1088

The Law Offices of Frank R. Cruz announces an investigation of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) on behalf of investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ERASCA, INC. (ERAS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YO...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.06.2026       Erasca
US29479A1088

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients wi...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       Erasca
US29479A1088

SAN FRANCISCO, June 4, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank  $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015).  The challenge is being waged by competitor Revolution Me...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 28.05.2026       Erasca
US29479A1088

SAN FRANCISCO, May 28, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank  $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015).  The challenge is being waged by competitor Revolution Me...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 21.05.2026       Erasca
US29479A1088

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Erasca
US29479A1088

SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Investors in Erasca, Inc. (NASDAQ: ERAS) saw the price of their shares tank  $9.25 (-48%) on April 28, 2026 after the company announced that it is facing a legal challenge to intellectual property claims for its lead product candidate (ERAS-0015).  The challenge is being waged by competitor Revolution Me...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mi., 20.05.2026       Erasca
US29479A1088

The law firm of Kirby McInerney LLP continues its investigation on behalf of Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happe...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 15.05.2026       Erasca
US29479A1088

NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mi., 13.05.2026       Erasca
US29479A1088

The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mo., 11.05.2026       Erasca
US29479A1088

ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab ERAS-0015, a potentially best-in-class pan-RAS molecular glue, is being evaluated in combination with pembrolizumab...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 07.05.2026       Erasca
US29479A1088

NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company") (NASDAQ: ERAS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Erasca
US29479A1088

Boston, Massachusetts--(Newsfile Corp. - May 1, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Erasca
US29479A1088

Boston, Massachusetts--(Newsfile Corp. - April 29, 2026) - Block & Leviton is investigating Erasca, Inc. (NASDAQ: ERAS) for potential securities law violations. Investors who have lost money in their Erasca, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blocklevi...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Erasca
US29479A1088

Conference call and live webcast today at 4:30 PM Eastern Time Conference call and live webcast today at 4:30 PM Eastern Time...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 05.03.2026       Erasca
US29479A1088

ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 23.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shar...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 22.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. Th...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Di., 20.01.2026       Erasca
US29479A1088

SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 mill...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mi., 14.01.2026       Erasca
US29479A1088

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /CNW/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a loomin...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mi., 14.01.2026       Erasca
US29479A1088

Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Jan. 14, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The precision oncology market is hitting a massive growth spurt, projected to rocket from $110 billion toward a staggering $225.65 billion by 2032[1]. This gold rush is accelerating as Big Pharma giants scramble to survive a...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Mo., 12.01.2026       Erasca
US29479A1088

Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Erasca
US29479A1088

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /PRNewswire/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total can...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Erasca
US29479A1088

Issued on behalf of GT Biopharma, Inc.VANCOUVER, BC, Dec. 11, 2025 /CNW/ -- Equity Insider News Commentary – November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches[1]. The global anticancer drug market now values immunotherapies at over 45% of total cancer dru...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Erasca
US29479A1088

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 8th Annual Evercore Healthcare Conference being held at the L...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 29.05.2025       Erasca
US29479A1088

SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in June 2025 and...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Di., 13.05.2025       Erasca
US29479A1088

Early entry of RAS-targeting franchise into clinic enabled by strong execution...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Di., 25.03.2025       Erasca
US29479A1088

Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Do., 20.03.2025       Erasca
US29479A1088

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 31.01.2025       Erasca
US29479A1088

SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Di., 05.11.2024       Erasca
US29479A1088

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also p...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 17.05.2024       Erasca
US29479A1088

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink
Fr., 17.05.2024       Erasca
US29479A1088

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a p...
Zur Nachricht
Erasca
Charts & Research Termsheets Terminal
Permalink